Medicinal Products

AMOXICILLIN / AC CLAV Enf GNR 100 mg / 12.5 mg / ml

Generic drug of Augmentin Child
Therapeutic class: Infectiology - Parasitology
active ingredients: Amoxicillin, Clavulanic acid
laboratory: Paucourt

Powder for oral suspension
Box of 1 vial (+ syringe for oral administration) of 60 ml
All forms


They arise from the antibacterial activity and pharmacokinetic characteristics of this drug. They take into account both the clinical studies it has given and its place in the range of antibacterial products currently available.
They are limited to infections due to known sensitive organisms, especially in certain situations where the bacterial species responsible for the infection can be multiple and / or resistant to the currently available antibiotics.
On this basis, this drug is of particular interest in the following indications:
- acute otitis media of young children, recurrent ear infections,
- sinusitis,
- recurrent tonsillitis, chronic tonsillitis,
- low respiratory infections of the child from 30 months to 5 years,
- superinfections of chronic bronchopulmonary diseases,
- recurrent or complicated urinary tract infections excluding prostatitis,
- severe stomatological infections: abscesses, phlegmons, cellulitis, periodontitis.
Official recommendations concerning the appropriate use of antibacterials should be taken into account.

Dosage AMOXICILLIN / AC CLAV Enf GNR 100 mg / 12.5 mg / ml Powder for oral suspension Box of 1 vial (+ syringe for oral administration) of 60 ml

Dosages expressed as amoxicillin:
Child over 30 months old :
- in patients with normal renal function :
80 mg / kg / day in three doses, without exceeding the dosage of 3 g per day.
- in patients with renal insufficiency older than 30 months :
. Creatinine clearance greater than 30 ml / min: no dose adjustment necessary.
. creatinine clearance between 10 and 30 ml / min: 15 mg / kg / maximum dose, 2 times daily.
. creatinine clearance less than 10 ml / min: 15 mg / kg / day maximum.
Hemodialysis: 15 mg / kg / day and 15 mg / kg added during and after dialysis.
Administration mode :
This medicine is administered orally.
The administration is done with the syringe for oral administration graduated in kilos.
The dose per dose is indicated, depending on the weight of the child, on the plunger of the oral syringe graduated in kilograms. The dose is therefore read directly on the graduations of the syringe for oral administration. Thus, the indicated weight corresponds to the dose for a catch. Three takes a day are needed.
For example, graduation number 20 corresponds to the dose to be administered per dose for a child of 20 kg, three times a day.
Take the medicine preferably at the beginning of the meal.

Against indications

This medicine MUST NEVER BE USED in case of:
- allergy to antibiotics in the beta-lactams group (penicillins, cephalosporins): take into account the risk of cross-reactivity with antibiotics of the cephalosporin family;
- infectious mononucleosis (increased risk of cutaneous phenomena);
- history of liver injury related to the amoxicillin / clavulanic acid combination;
- phenylketonuria, due to the presence of aspartame.
This medicine SHOULD NOT BE USED in combination with methotrexate (see interactions).

Side effects Amoxicillin / AC Clav Enf Gnr

- Gastrointestinal manifestations: nausea, vomiting, possibility of gastrointestinal overinfections of candida, diarrhea (more frequent in children than in adults), loose stools, dyspepsia and abdominal pain.
Some cases of pseudomembranous colitis have been reported.
- Allergic manifestations, including urticaria, eosinophilia, angioedema, difficulty breathing, exceptionally anaphylactic shock.
- Maculopapular rashes of allergic origin or not.
Very rarely, some cases of Stevens-Johnson syndrome, erythema multiforme, and exfoliative dermatitis have been reported.
- Other events have been reported more rarely:
. cases of hepatitis, usually cholestatic or mixed, have occasionally been reported. These cases seem to be more likely to occur in elderly and male patients and during treatment for more than 10 days, especially for treatments longer than 15 days. Symptoms, including jaundice that appears consistent, occur during or at the end of treatment, but may occur a few weeks after stopping. Histopathological examination of the liver usually reveals centrilobular cholestasis. The evolution is generally favorable but can be prolonged by a few weeks.
Some extremely rare cases of fatal evolution have been observed.
. moderate and asymptomatic increases in ASAT, ALT or alkaline phosphatase;
. acute interstitial nephritis;
. leukopenia, thrombocytopenia and reversible anemia.

Popular Posts

Category Medicinal Products, Next Article